Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Concept Videos

Dementia01:30

Dementia

702
Dementia is a collective term for cognitive disorders primarily affecting memory, thinking, and reasoning. It is not a specific disease but a syndrome, with Alzheimer's disease being the most common cause, accounting for approximately 60-80% of cases. Other types include vascular dementia, Lewy body dementia, and frontotemporal dementia. Dementia affects millions worldwide, particularly older adults, though it is not a normal part of aging.
The progression of dementia is generally gradual....
702
Parkinson's Disease: Overview01:15

Parkinson's Disease: Overview

2.4K
Neurodegenerative disorders are progressive diseases that cause irreversible damage and loss to neurons in specific brain areas. Examples of these disorders include Parkinson's disease, Alzheimer's disease, Multiple Sclerosis (MS), and Amyotrophic Lateral Sclerosis (ALS). These disorders share characteristics such as proteinopathies, selective neuronal vulnerability, and a complex interplay between genetic and environmental factors. The primary therapeutic goal for these conditions is...
2.4K
Alzheimer's Disease: Overview01:26

Alzheimer's Disease: Overview

2.0K
Alzheimer's Disease (AD) is a continually advancing neurodegenerative disorder, distinguished by escalating memory loss, cognitive dysfunction, and dementia. The disease unfolds in three stages: preclinical, mild cognitive impairment (MCI), and dementia. Its onset is insidious, and the progression gradual, with the cause not well explained by other disorders.
The clinical diagnosis of AD hinges on the presence of memory and other cognitive impairments. Biomarkers, such as changes in Aβ...
2.0K
Neural Regulation01:37

Neural Regulation

44.8K
Digestion begins with a cephalic phase that prepares the digestive system to receive food. When our brain processes visual or olfactory information about food, it triggers impulses in the cranial nerves innervating the salivary glands and stomach to prepare for food.
44.8K
Lysosomal Hydrolases01:22

Lysosomal Hydrolases

4.7K
Lysosomes are the site for the degradation of macromolecules and biological polymers released during membrane trafficking events such as secretory, endocytic, autophagic, and phagocytic pathways. The membrane-enclosed area of the lysosome, called the lumen, contains hydrolytic enzymes active in an acidic environment. These acid hydrolases are functional at a pH between 4.5 and 5 and are involved in cellular processes such as cell signaling, energy metabolism, restoration of the plasma membrane,...
4.7K
Parkinson's Disease: Treatment01:24

Parkinson's Disease: Treatment

1.3K
Neurodegenerative disorders, such as Parkinson's Disease (PD), involve the gradual and irreversible destruction of neurons in particular brain areas. These disorders exhibit standard features like proteinopathies, selective vulnerability of some neurons, and an interaction of intrinsic properties, genetics, and environmental influences in neural injury.
Parkinson's Disease is primarily a result of the loss of dopaminergic neurons in the substantia nigra pars compacta. The cornerstone of...
1.3K

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Shared brain transcriptomic signature in TDP-43 type A FTLD patients with or without GRN mutations.

Brain : a journal of neurology·2021
Same author

The contribution of behavioral features to caregiver burden in FTLD spectrum disorders.

Alzheimer's & dementia : the journal of the Alzheimer's Association·2021
Same author

Posterior cortical atrophy phenotypic heterogeneity revealed by decoding <sup>18</sup>F-FDG-PET.

Brain communications·2021
Same author

The temporal onset of the core features in dementia with Lewy bodies.

Alzheimer's & dementia : the journal of the Alzheimer's Association·2021
Same author

Rare PSAP Variants and Possible Interaction with GBA in REM Sleep Behavior Disorder.

Journal of Parkinson's disease·2021
Same author

Regional Brain Stiffness Analysis of Dementia with Lewy Bodies.

Journal of magnetic resonance imaging : JMRI·2021
Same journal

Inherited retinal degenerations: clinical phenotypes and emerging therapies.

Lancet (London, England)·2026
Same journal

Documenting hospice care.

Lancet (London, England)·2026
Same journal

After the wood chipper.

Lancet (London, England)·2026
Same journal

Assisted dying and the silencing of medicine's next generation.

Lancet (London, England)·2026
Same journal

Linguistic pragmatism: a woman with progressive abdominal pain in Thailand.

Lancet (London, England)·2026
Same journal

Medical compartmentalisation: a patient with chromosome 22q11.2 deletion syndrome in Japan.

Lancet (London, England)·2026
See all related articles

Related Experiment Video

Updated: Mar 29, 2026

Studying Pre-formed Fibril Induced &#945;-Synuclein Accumulation in Primary Embryonic Mouse Midbrain Dopamine Neurons
10:03

Studying Pre-formed Fibril Induced α-Synuclein Accumulation in Primary Embryonic Mouse Midbrain Dopamine Neurons

Published on: August 16, 2020

11.5K

Lewy body dementias.

Zuzana Walker1, Katherine L Possin2, Bradley F Boeve3

  • 1Division of Psychiatry, University College London, London, UK; North Essex Partnership University NHS Foundation Trust, Epping, UK.

Lancet (London, England)
|November 24, 2015
PubMed
Summary
This summary is machine-generated.

Lewy body dementias, the second most common dementia in older adults, are often misdiagnosed. Recent advances focus on improving diagnosis and developing treatments targeting underlying pathology for better patient management.

More Related Videos

Abbiategrasso Brain Bank Protocol for Collecting, Processing and Characterizing Aging Brains
12:28

Abbiategrasso Brain Bank Protocol for Collecting, Processing and Characterizing Aging Brains

Published on: June 3, 2020

18.5K
Technique for Intranasal Administration of &#945;-Synuclein Aggregates
04:49

Technique for Intranasal Administration of α-Synuclein Aggregates

Published on: November 8, 2024

1.2K

Related Experiment Videos

Last Updated: Mar 29, 2026

Studying Pre-formed Fibril Induced &#945;-Synuclein Accumulation in Primary Embryonic Mouse Midbrain Dopamine Neurons
10:03

Studying Pre-formed Fibril Induced α-Synuclein Accumulation in Primary Embryonic Mouse Midbrain Dopamine Neurons

Published on: August 16, 2020

11.5K
Abbiategrasso Brain Bank Protocol for Collecting, Processing and Characterizing Aging Brains
12:28

Abbiategrasso Brain Bank Protocol for Collecting, Processing and Characterizing Aging Brains

Published on: June 3, 2020

18.5K
Technique for Intranasal Administration of &#945;-Synuclein Aggregates
04:49

Technique for Intranasal Administration of α-Synuclein Aggregates

Published on: November 8, 2024

1.2K

Area of Science:

  • Neurology
  • Neuroscience
  • Geriatrics

Background:

  • Dementia is a significant global health concern, with Alzheimer's disease receiving substantial research focus.
  • Lewy body dementias (LBD), encompassing dementia with Lewy bodies and Parkinson's disease dementia, are the second most prevalent degenerative dementias in individuals over 65.
  • Despite their prevalence, LBD often suffer from underdiagnosis and suboptimal patient management.

Purpose of the Study:

  • To review recent advancements in the diagnosis and understanding of Lewy body dementias.
  • To highlight the challenges and future directions for developing effective treatments for LBD.
  • To emphasize the need for improved diagnostic accuracy and targeted therapies.

Main Methods:

  • Review of pertinent scientific literature from the past 10 years.
  • Analysis of progress in refining diagnostic criteria for LBD.
  • Evaluation of the role of imaging and biomarkers in LBD diagnosis.

Main Results:

  • Significant efforts have been made to enhance diagnostic accuracy for LBD.
  • Shared pathophysiology between dementia with Lewy bodies and Parkinson's disease dementia is recognized.
  • Progress has been made in identifying diagnostic markers and understanding disease mechanisms.

Conclusions:

  • Improved diagnostic refinement and biomarker development are crucial for LBD.
  • Future treatments must target the pathological mechanisms of LBD, ideally pre-symptomatically.
  • Clarifying pathogenesis is essential for developing disease-modifying therapies for LBD.